Table 4.
Treatment-related adverse events.
| Number of patients with adverse events | Anti-PD-1 (n = 35) |
Anti-PD-1 plus chemotherapy (n = 31) |
||
|---|---|---|---|---|
| Grade 1-2 | Grade 3-4 | Grade 1-2 | Grade 3-4 | |
| Fever | 12 (33.3%) | 0 | 10 (32.3%) | 0 |
| Fatigue | 3 (8.6%) | 0 | 3 (9.7%) | 0 |
| Hyperthyroidism | 6 (17.1%) | 0 | 0 | 0 |
| Hypothyroidism | 4 (11.4%) | 0 | 4 (12.9%) | 0 |
| Gastrointestinal system | ||||
| Diarrhea | 5 (14.3%) | 0 | 4 (12.9%) | 0 |
| Nausea or vomiting | 6 (17.1%) | 0 | 7 (22.6%) | 0 |
| Increased alanine aminotransferase | 8 (22.8%) | 2 (5.7%) | 8 (25.8%) | 3 (9.7%) |
| Increased aspartate aminotransferase | 6 (17.1%) | 4 (11.4%) | 7 (22.6%) | 1 (3.2%) |
| Increased amylase or lipase | 0 | 0 | 1 (3.2%) | 0 |
| Skin | ||||
| Rash or pruritus | 7 (20.0%) | 0 | 4 (12.9%) | 2 (6.5%) |
| RCCEP | 7 (20.0%) | 0 | 8 (25.8%) | 0 |
| Blood suppression | ||||
| Anaemia | 4 (11.4%) | 0 | 3 (9.7%) | 1 (3.2%) |
| Thrombocytopenia | 4 (11.4%) | 0 | 2 (6.5%) | 0 |
| Leukopenia | 12 (34.3%) | 4 (11.4%) | 6 (19.4%) | 8 (25.8%) |
PD-1 = programmed death −1. RCCEP = Reactive cutaneous capillary endothelial proliferation.